COL3A1 and Ehlers-Danlos syndrome, vascular type: Concerning the potential of gene therapy for treating vEDS, RNA interference (RNAi) technology has successfully targeted the expression of the mutant COL3A1 allele harboring a glycine substitution (p.Gly252Val) in patients’ dermal fibroblasts.